BackApimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Other Liabilities

Track Apimeds Pharmaceuticals US's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Apimeds Pharmaceuticals US Other Liabilities History

Loading

Apimeds Pharmaceuticals US vs. peers: Other Liabilities Comparison

Loading

Apimeds Pharmaceuticals US Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Apimeds Pharmaceuticals US (APUS) FAQ

As of the most recent data (March 2026), APUS shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, APUS's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Apimeds Pharmaceuticals US is outperforming or lagging.

Tracking APUS's other liabilities over time shows whether Apimeds Pharmaceuticals US is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has Apimeds Pharmaceuticals US's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.